Pure Global

Control material for semi-quantitative assays for cardiolipin-resistant IgG antibodies, ß2GP1 and cardiolipin-resistant IgM antibodies, ß2GP1 - Vietnam Registration 270667

Access comprehensive regulatory information for Control material for semi-quantitative assays for cardiolipin-resistant IgG antibodies, ß2GP1 and cardiolipin-resistant IgM antibodies, ß2GP1 in Vietnam's medical device market through Pure Global AI's free database. is registered under number 270667 and manufactured by Biokit, S.A., Spain. The authorized representative in Vietnam is VIETNAM HEALTH AND ENVIRONMENT CO., LTD.

This page provides complete technical specifications, regulatory compliance details, 1 companies making similar products including Biokit, S.A., Spain, and 1 recent registrations in the same category. Pure Global AI offers free access to 300,000+ Vietnamese medical device registrations, helping global MedTech companies navigate Vietnam MOH regulations, identify competitors, and discover partnership opportunities efficiently.

Free Database
Powered by Pure Global AI
300,000+ Devices
1 Competitors
1 Recent Registrations
270667
Registration Details
Vietnam MOH Registration: 270667
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing

Device Details

Control material for semi-quantitative assays for cardiolipin-resistant IgG antibodies, ß2GP1 and cardiolipin-resistant IgM antibodies, ß2GP1
VN: Vật liệu kiểm soát các xét nghiệm bán định lượng kháng thể IgG kháng cardiolipin, ß2GP1 và kháng thể IgM kháng cardiolipin, ß2GP1
QUANTA Flash aPL Multi Controls

Registration Details

270667

QUANTA Flash aPL Multi Controls

701060

Company Information

Spain

Inova Diagnostics, Inc., USA

United States

Technical Details

Hộp

Dates and Status

Sep 30, 2022

Mar 31, 2023

Còn hiệu lực

Pricing

9500400 VND

Companies Making Similar Products
Companies providing products similar to "Control material for semi-quantitative assays for cardiolipin-resistant IgG antibodies, ß2GP1 and cardiolipin-resistant IgM antibodies, ß2GP1"